

| PI | DEPARTMENT | FUNDING AGENCY | PROJECT TITLE | PROJECT BEGIN DATE | PROJECT END DATE | AMOUNT AWARDED | AWARD DATE | SUB. AGENCY |
|--------------|----------------------------|-------------------------------|--|--------------------|------------------|----------------|------------|-------------|
| BERTHOLF R L | UFHSCJ/PATHOLOGY | ROCHE DIAGNOSTICS CORPORATION | PERFORMANCE EVALUATION OF GENTAMICIN AND THEOPHYLLINE ONLINETDM ON HITACHI SYSTEMS | 01/15/2002 | 06/30/2002 | \$10,000.00 | 06/30/2002 | |
| BOTTOM W D | MEDICINE | CENTRAL FL AREA HLTH EDUC CTR | INCREASING AVAILABILITY AND IMPROVING THE QUALITY OF HEALTH WORKFORCE EDUCATION AND TRAINING | 07/01/2001 | 12/31/2002 | \$4,000.00 | 06/25/2002 | |
| BURKE B E | ANATOMY & CELL BIOLOGY | NATL INSTITUTES OF HEALTH | THE ROLE OF NUCLEAR LAMINS IN MUSCLE DISEASE | 07/01/2002 | 03/31/2007 | \$300,493.00 | 06/19/2002 | |
| CRAWFORD J M | PATHOLOGY & LABORATORY MED | THOMAS JEFFERSON UNIVERSITY | GUANYLYL CYCLASE C AS A BIOMARKER FOR COLORECTAL CANCER | 02/25/2002 | 01/31/2003 | \$62,886.00 | 06/17/2002 | NIH |
| DESNOYERS R | MEDICINE | THOMAS JEFFERSON UNIVERSITY | GUANYLYL CYCLASE C AS A BIOMARKER FOR COLORECTAL CANCER | 02/25/2002 | 01/31/2003 | \$46,288.00 | 06/07/2002 | NIH |
| FINIEWICZ K | CANCER CENTER | GENTA INC | RANDOMIZED STUDY OF FLUDARABINE & CYCLOPHOSPHOAMIDE W/WO GENASENSE...IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC | 07/26/2001 | 05/08/2003 | \$14.27 | 06/27/2002 | |
| FINIEWICZ K | CANCER CENTER | SANGSTAT MEDICAL CORP | AN OPN-LBL PROSPECTIVE STRATIFIED RNDMZD CNTRL MULTI-CTR PHASE IIB STDY OF THE IMPACT OF THYMOGLOBULIN THRYPY ON TRANS | 12/20/2000 | 09/27/2002 | \$2,727.66 | 06/28/2002 | |

| PI | DEPARTMENT | FUNDING AGENCY | PROJECT TITLE | PROJECT BEGIN DATE | PROJECT END DATE | AMOUNT AWARDED | AWARD DATE | SUB. AGENCY |
|--------------|------------------------------|-------------------------------|--|--------------------|------------------|----------------|------------|-------------|
| FINIEWICZ K | CANCER CENTER | GENOME THERAPEUTICS CORP | 0502: PHASE II RNDMZD PRL EL PL CB-CNTRLD DBL-BL MULTICTR EFFI& SAF STDY OF RAMOPLANIN & PL CB IN NEUTROPENIC ONCOLOGY..... | 06/07/2000 | 12/31/2003 | \$9,132.61 | 06/27/2002 | |
| FORSMARK C E | MEDICINE | ASTRAZENECA | A COMPARATIVE EFFICACY AND SAFETY STUDY OF NEXIUM DELAYED RELEASE CAPSULES (40MG QD & 20MG QD) VERSUS RANITIDINE..... | 04/08/2002 | 03/05/2003 | \$540.00 | 06/26/2002 | |
| FROST S C | BIOCHEMISTRY & MOLECULAR BIO | AM HEART ASSOCIATION | MOLECULAR REGULATION OF INSULIN RECEPTOR PROCESSING IN PHOSPHOMANNOMUTASE-DEFICIENT FIBROBLASTS/NATL CTR RES PROGRA | 07/01/2002 | 06/30/2004 | \$60,000.00 | 06/28/2002 | |
| GABRIELLI A | ANESTHESIOLOG Y | INVERESK RESEARCH | COMPARISN OF OMEPRAZOLE SODIUM BICARBONATE IMMEDIATE-RELEASE POWDER FOR SUSPENSION TO INTRAVENOUS CIMETIDINE FOR THE..... | 05/20/2002 | 03/11/2003 | \$5,500.00 | 06/20/2002 | |
| GEISER E A | MEDICINE | U F RESEARCH FOUNDATION MISC | UFRF MISCELLANEOUS | 06/08/2001 | 06/30/2005 | \$171.71 | 06/26/2002 | |
| GUTHRIE T H | UFHSCJ/MEDICIN E | SANOFI-SYNTHELABO RESEARCH US | A MULTICTR, OPEN-LBEL, RANDOMIZED, TWO-ARM STUDY OF IRINOTECAN (CPT-11) VS THE COMBINATION OF OXALIPLATIN+ IRNNOTECON AS 2ND | 01/30/2002 | 01/29/2003 | \$1,500.00 | 06/21/2002 | |

| PI | DEPARTMENT | FUNDING AGENCY | PROJECT TITLE | PROJECT BEGIN DATE | PROJECT END DATE | AMOUNT AWARDED | AWARD DATE | SUB. AGENCY |
|---------------|----------------------------|-----------------------------|--|--------------------|------------------|----------------|------------|-------------|
| HAUSWIRTH W W | OPHTHALMOLOGY | MOUNT SINAI MEDICAL CENTER | MOLECULAR BIOLOGY OF AAV: ANTI-NEOVASCULARIZATION THERAPY | 05/01/2002 | 01/01/2003 | \$207,347.00 | 06/17/2002 | |
| ICZKOWSKI K A | PATHOLOGY & LABORATORY MED | AM CANCER SOCIETY | ABERRANT MESSENGER CD44 RNA EXPRESSION IN PROSTATIC ADENOCARCINOMA | 07/01/2002 | 06/30/2005 | \$183,000.00 | 06/26/2002 | |
| JARIKOV S I | MEDICINE | AM LUNG ASSOCIATION - FL | PHOSPHORYLATION REGULATES CAT-1 TRANSPORT ACTIVITY IN PULMONARY ENDOTHELIAL CELLS | 07/01/2002 | 06/30/2003 | \$59,764.00 | 06/20/2002 | |
| JARIKOV S I | MEDICINE | AM HEART ASSOCIATION | LOCALIZATION AND REGULATION OF THE CAT-1 L-ARGININE TRANSPORTER IN CAVEOLAE OF ENDOTHELIAL CELLS | 07/01/2002 | 06/30/2006 | \$80,000.00 | 06/28/2002 | |
| LAYON A J | ANESTHESIOLOGY | MEDICAL COLLEGE OF VIRGINIA | MITOCHONDRIA RELATED EVENTS IN TRAUMATIC BRAIN INJURY | 09/01/2001 | 08/31/2002 | \$154,935.00 | 06/24/2002 | |
| MCCARLEY D | CANCER CENTER | LIGAND PHARMACEUTICALS INC | RANDOMIZED PHASE III TRIAL COMPARING TARGRETIN CAPSULES/ CISPLATIN/VINORELBINE V. CISPLATIN/VINORELBINE IN CHEMOTHERAP | 04/01/2002 | 04/03/2003 | \$4,000.00 | 06/03/2002 | |
| MONROE JR V S | MEDICINE | COR THERAPEUTICS INC | CRUSADE - IRB EXPENSE MATCH TO DUKE UNIVERSITY UPN 02040103 | 04/04/2002 | 01/24/2003 | \$1,500.00 | 06/04/2002 | |

| PI | DEPARTMENT | FUNDING AGENCY | PROJECT TITLE | PROJECT BEGIN DATE | PROJECT END DATE | AMOUNT AWARDED | AWARD DATE | SUB. AGENCY |
|-------------|-------------------------------|------------------------------|--|--------------------|------------------|----------------|------------|-------------|
| MOZINGO D W | SURGERY | INVERESK RESEARCH | COMPARISON OF OMEPRAZOLE SODIUM BICARBONATE IMMEDIATE-RELEASE POWDER FOR SUSPENSION TO INTRAVENOUS CIMETIDINE FOR THE | 05/20/2002 | 03/11/2003 | \$5,500.00 | 06/20/2002 | |
| PAULY D F | MEDICINE | MDS PHARMA SERVICES CLIN RES | REVIVE-RNDMZD MLT-CTR EVAL OF INTRAVENOUS LEVOSIMENDAN EFFICVS PLACEBO IN SHORT TERM TREATMENT OF DECOMPENSATED ... | 08/23/2001 | 01/17/2003 | \$8,447.97 | 06/24/2002 | |
| PAULY D F | MEDICINE | AM HOME PRODUCTS CORP | RENAISSANCE CORE; POLYMORPHISMS OF THE 75-KDA TNF RECEPTOR IN PATIENTS IN THE ENBREL STUDY | 01/09/2002 | 01/08/2003 | \$15,000.00 | 06/24/2002 | |
| PIGOTT T A | PSYCHIATRY | ELI LILLY & COMPANY | LY544344 COMPARED WITH PLACEBO IN PATIENTS WITH GENERALIZED ANXIETY DISORDER | 05/31/2002 | 04/18/2003 | \$20,000.00 | 06/14/2002 | NIH |
| RATHORE M H | UFHSCJ/PEDIATRICS | AM HOME PRODUCTS CORP | PROTOCOL D139-P4:A PHASE III,RANDOMZED DOUBLE-BLIND MULTICTRSTUDY TO COMPARE THE SAFETY...9-VALENT PNEUMOCOCCAL SEROGROUP | 04/05/2002 | 04/05/2003 | \$19,863.00 | 06/30/2002 | |
| SAMRAJ G P | COMMUNITY HEALTH & FAMILY MED | ABBOTT LABORATORIES | A COMPARISON OF THE SAFETY AND EFFICACY OF ABT-773 150MG BID TO LEVOFLOXACIN 500MG QD FOR THE TREATMENT OF COMMUNITY | 06/21/2002 | 11/15/2002 | \$1,248.28 | 06/25/2002 | |

| PI | DEPARTMENT | FUNDING AGENCY | PROJECT TITLE | PROJECT BEGIN DATE | PROJECT END DATE | AMOUNT AWARDED | AWARD DATE | SUB. AGENCY |
|--------------|------------------------------|--------------------------------|--|--------------------|------------------|----------------|------------|-------------|
| SANDS M | UFHSCJ/MEDICINE | INVERESK RESEARCH | A PHASE-III OPEN-LABEL SAFETY STUDY OF T-20/R0 29-9800 (HIV1INHIBITOR) IN COMBINATION W. ORAL ANTIRETROVIRALS IN PATIENT | 04/29/2002 | 04/28/2003 | \$144.00 | 06/30/2002 | |
| SANDS M | UFHSCJ/MEDICINE | INGENIX PHARMACEUTICAL SERVICE | DAILY ANTIRETROVIRAL THRPY (DART-II)AN OPEN-LABEL, SNGL-ARM,PROSPCTV, MULTICTR CLINTRL TO EVAL THE EFFIC & SAF OF | 04/25/2002 | 04/25/2004 | \$4,500.00 | 06/10/2002 | |
| SANDS M | UFHSCJ/MEDICINE | SCHERING-PLOUGH CORP | PHASE III STUDY OF PEG-INTRON IN HEAVILY TREATMENT EXPERIENECEED HIV-INFECTED PATIENTS--PROTOCOL P00738 | 02/28/2002 | 03/31/2003 | \$7,200.00 | 06/10/2002 | |
| SANDS M | UFHSCJ/MEDICINE | ORTHO BIOTECH PRODUCTS LP | A RANDOMIZED,OPEN-LBL STUDY TO COMPARE THE EFFECT OF PROCRIT(EPOETIN ALFA)3 TIMES WKLY VERSUS ONCE WKLY IN THE TREATMENT | 01/11/2002 | 03/13/2003 | \$16,020.00 | 06/30/2002 | |
| SCHELL S R | SURGERY | THOMAS JEFFERSON UNIVERSITY | GUANYLYL CYCLASE C AS A BIOMARKER FOR COLORECTAL CANCER | 02/25/2002 | 01/31/2003 | \$70,999.00 | 06/17/2002 | NIH |
| SCOTT E W | CANCER CENTER | NATL INSTITUTES OF HEALTH | DEFINING THE HUMAN HEMANGIOBLAST | 07/01/2002 | 06/30/2004 | \$145,000.00 | 06/20/2002 | |
| SHENKMAN E A | INST FOR CHILD HEALTH POLICY | DEPT OF HEALTH | EVALUATION FOR MEDICAL ELIGIBILITY SCREENING | 07/01/2002 | 06/30/2003 | \$35,806.00 | 06/27/2002 | |

| PI | DEPARTMENT | FUNDING AGENCY | PROJECT TITLE | PROJECT BEGIN DATE | PROJECT END DATE | AMOUNT AWARDED | AWARD DATE | SUB. AGENCY |
|-----------------|------------------------------|-------------------------------|--|--------------------|------------------|----------------|------------|----------------------|
| SHENKMAN E A | INST FOR CHILD HEALTH POLICY | DEPT OF HEALTH | CHILDREN'S MEDICAL SERVICES TO CONDUCT SATISFACTION SURVEYS (COQBI) | 07/01/2002 | 06/30/2003 | \$80,949.00 | 06/26/2002 | |
| SILVERSTEIN J H | PEDIATRICS | ASTRAZENECA | AN EXTENSION OF TRIAL 1033US/0006 TO ASSESS THE SAFETY, TOLERABILITY & EFFICACY OF ANASTROZOLE (ZD1033 ARIMIDEX) IN THE | 12/15/2000 | 03/06/2003 | \$150.00 | 06/05/2002 | |
| SPOTNITZ W D | SURGERY | BAXTER HEALTHCARE CORP | HIC#9688 BAXTER/CERUS PROTOCOL#RBC3A01 S-303 TREATED RED BLOOD CELL USE IN PATIENTS REQUIRING ACUTE TRANSFUSION | 12/01/2001 | 12/31/2005 | \$10,610.00 | 06/24/2002 | |
| VALCANTE G | PSYCHIATRY | UNIVERSITY OF SOUTH FLORIDA | POSITIVE BEHAVIORAL SUPPORT PROJECT | 04/01/2002 | 09/30/2002 | \$8,529.39 | 06/06/2002 | US DEPT OF EDUCATION |
| VALENTINE J F | MEDICINE | NATL INSTITUTES OF HEALTH | BASIC RESEARCH TRAINING IN GASTROENTEROLOGY & HEPATOLOGY | 07/01/2002 | 06/30/2003 | \$120,015.00 | 06/24/2002 | |
| VILLARET D B | OTOLARYNGOLOGY | DAIICHI PHARMACEUTICAL CO LTD | PHASE III MULTI-CTR RNDMZD DBL-BL PLCB-CNTRL STDY TO ASSESS EFFIC & SAF OF CEVIMELINE HCI IN TRTMNT OF XEROSTOMIA SECOND | 04/22/2002 | 06/21/2002 | \$4,000.00 | 06/06/2002 | |
| WILLIAMS R S | OBSTETRICS & GYNECOLOGY | AM HOME PRODUCTS CORP | A DOUBLE-BLIND,RANDOMIZED,PLACEBO & ACTIVE CONTROLLED SAFETY& EFFICACY STUDY OF BAZEDOXIFENE/CONJUGATED ESTROGEN..... | 01/01/2002 | 03/05/2003 | \$20,000.00 | 06/03/2002 | |

| PI | DEPARTMENT | FUNDING AGENCY | PROJECT TITLE | PROJECT BEGIN DATE | PROJECT END DATE | AMOUNT AWARDED | AWARD DATE | SUB. AGENCY |
|--------------|-----------------|-------------------------------|--|--------------------|------------------|----------------|------------|-------------|
| WINGARD J R | CANCER CENTER | ASSOCIATES OF CAPE COD INC | ASSOCIATES OF CAPE COD BETA - (1,3) GLUCAN ASSAY FOR THE DETECTION OF FUNGEMIAS | 09/17/2001 | 09/16/2002 | \$3,375.00 | 06/07/2002 | |
| WINGARD J R | CANCER CENTER | SCHERING-PLOUGH RESEARCH INST | A RETROSPECTIVE STUDY TO ESTABLISH AN HISTORICAL DATABASE ON THE EFFICACY OF STANDARD ANTIFUNGAL THERAPY IN PATIENTS WITH | 11/14/2001 | 11/13/2002 | \$3,687.50 | 06/17/2002 | |
| XIAO L | CANCER CENTER | FLIGHT ATTENDANT MED RES INST | PKC- EXPRESSION ON THE OUTCOME OF CHEMOTHERAPY | 07/01/2002 | 06/30/2004 | \$217,000.00 | 06/12/2002 | |
| ZENNI II M M | UFHSCJ/MEDICINE | AVENTIS | A PHASE IV, OPEN-LBL, MULTICTR STDY IN HIGH RISK PATIENT WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME:(SYNERGY)CT | 02/25/2002 | 02/25/2004 | \$600.00 | 06/07/2002 | |
| ZHANG J | MEDICINE | AM LUNG ASSOCIATION - FL | NITRIC OXIDE-INDUCED LUNG ENDOTHELIAL INJURY AND APOPTOSIS | 07/01/2002 | 06/30/2003 | \$60,000.00 | 06/27/2002 | |